Novel T Cell Engager Targeting CD3 and CDH17 for the Treatment of Solid Tumors

Cadherin-17 (CDH17) is a highly promising target for T-cell engager (TCE) therapy due to its elevated expression in gastrointestinal tumors and restricted normal tissue distribution. However, conventional CD3-engaging TCEs are frequently limited by cytokine release syndrome (CRS). Using a fully humanized mouse platform, GemPharmatech identified cross-reactive CD3 and CDH17 binders and developed a novel CDH17×CD3 bispecific antibody. The lead candidate demonstrated potent, dose-dependent tumor cell killing comparable to a benchmark TCE, while inducing significantly lower levels of pro-inflammatory cytokines. This optimized TCE offers an improved therapeutic window and supports the translational development of safer bispecific antibodies for solid tumor treatment.